ANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 5,400 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $71.00, for a total transaction of $383,400.00. Following the completion of the sale, the chief executive officer owned 339,089 shares in the company, valued at $24,075,319. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $73.59 on Thursday. The company has a market cap of $1.69 billion, a P/E ratio of 15.86 and a beta of 0.45. The firm has a fifty day moving average price of $76.47 and a 200 day moving average price of $78.11. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 12 month low of $69.58 and a 12 month high of $98.55.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the firm earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Canaccord Genuity Group reduced their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock. Finally, Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ANIP. Penn Capital Management Company LLC raised its holdings in shares of ANI Pharmaceuticals by 2,058.9% in the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after buying an additional 131,030 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of ANI Pharmaceuticals during the second quarter worth about $6,597,000. CenterBook Partners LP acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at about $1,518,000. NFJ Investment Group LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $2,766,000. Finally, Walleye Capital LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $8,784,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.